Literature DB >> 34160781

Early manifestation of gait alterations in the Tg2576 mouse model of Alzheimer's disease.

Anna Csiszar1,2, Zoltan Ungvari3,4, Stefano Tarantini5,6, Adam Nyul-Toth1,7, Jordan DelFavero1, Peter Mukli1,8, Amber Tarantini1, Anna Ungvari1, Andriy Yabluchanskiy1.   

Abstract

There is strong clinical evidence that multifaceted gait abnormalities may be manifested at early stages of Alzheimer's disease (AD), are related to cognitive decline, and can be used as an early biomarker to identify patients at risk of progressing to full-blown dementia. Despite their importance, gait abnormalities have not been investigated in mouse models of AD, which replicate important aspects of the human disease. The Tg2576 is frequently used in AD research to test therapeutic interventions targeting cellular mechanisms contributing to the genesis of AD. This transgenic mouse strain overexpresses a mutant form of the 695 amino acid isoform of human amyloid precursor protein with K670N and M671L mutations (APPK670/671L) linked to early-onset familial AD. Tg2576 mice exhibit impaired cognitive functions and increased cortical and hippocampal soluble β-amyloid levels starting from 5 months of age and increased insoluble β-amyloid levels and amyloid plaques that resemble senile plaques associated with human AD by 13 months of age. To demonstrate early manifestations of gait dysfunction in this relevant preclinical model, we characterized gait and motor performance in 10-month-old Tg2576 mice and age-matched littermate controls using the semi-automated, highly sensitive, Catwalk XT system. We found that Tg2576 mice at the pre-plaque stage exhibited significantly altered duty cycle and step patterns and decreased stride length and stride time. Base-of-support, stride time variability, stride length variability, cadence, phase dispersions and gait symmetry indices were unaltered. The presence of measurable early gait abnormalities during the pre-plaque stages of AD in this relevant preclinical mouse model has direct translational relevance and supports the view that longitudinal monitoring of gait performance could be used in addition to behavioral testing to evaluate progression of the disease and to assess treatment efficacy.

Entities:  

Keywords:  Balance; Brain aging; Gait; Motor performance; Neurodegeneration; Neurodegenerative disease

Year:  2021        PMID: 34160781     DOI: 10.1007/s11357-021-00401-6

Source DB:  PubMed          Journal:  Geroscience        ISSN: 2509-2723            Impact factor:   7.713


  67 in total

1.  Pattern of extrapyramidal signs in Alzheimer's disease.

Authors:  Giuseppe Tosto; Sarah E Monsell; Stephen E Hawes; Richard Mayeux
Journal:  J Neurol       Date:  2015-09-04       Impact factor: 4.849

2.  Effects of Acetylcholinesterase Inhibitors on Balance and Gait Functions and Orthostatic Hypotension in Elderly Patients With Alzheimer Disease.

Authors:  Ahmet Turan Isik; Pinar Soysal; Cansu Usarel
Journal:  Am J Alzheimers Dis Other Demen       Date:  2016-08-31       Impact factor: 2.035

3.  Gait Disorder in a Cohort of Patients With Mild and Moderate Alzheimer's Disease.

Authors:  A Castrillo; L M García Olmos; F Rodríguez; J Duarte
Journal:  Am J Alzheimers Dis Other Demen       Date:  2015-09-22       Impact factor: 2.035

4.  Gait slowing as a predictor of incident dementia: 6-year longitudinal data from the Sydney Older Persons Study.

Authors:  L M Waite; D A Grayson; O Piguet; H Creasey; H P Bennett; G A Broe
Journal:  J Neurol Sci       Date:  2004-12-08       Impact factor: 3.181

5.  Gait speed or gait variability, which one to use as a marker of risk to develop Alzheimer disease? A pilot study.

Authors:  S Gillain; M Dramé; F Lekeu; V Wojtasik; C Ricour; J-L Croisier; E Salmon; J Petermans
Journal:  Aging Clin Exp Res       Date:  2015-06-16       Impact factor: 3.636

Review 6.  Loss of gait control assessed by cognitive-motor dual-tasks: pros and cons in detecting people at risk of developing Alzheimer's and Parkinson's diseases.

Authors:  Maroua Belghali; Nathalie Chastan; Fabien Cignetti; Damien Davenne; Leslie M Decker
Journal:  Geroscience       Date:  2017-05-27       Impact factor: 7.713

7.  Abnormality of gait as a predictor of non-Alzheimer's dementia.

Authors:  Joe Verghese; Richard B Lipton; Charles B Hall; Gail Kuslansky; Mindy J Katz; Herman Buschke
Journal:  N Engl J Med       Date:  2002-11-28       Impact factor: 91.245

8.  Spatio-temporal and kinematic gait analysis in patients with Frontotemporal dementia and Alzheimer's disease through 3D motion capture.

Authors:  Rosaria Rucco; Valeria Agosti; Francesca Jacini; Pierpaolo Sorrentino; Pasquale Varriale; Manuela De Stefano; Graziella Milan; Patrizia Montella; Giuseppe Sorrentino
Journal:  Gait Posture       Date:  2016-12-21       Impact factor: 2.840

9.  Motoric cognitive risk syndrome and the risk of dementia.

Authors:  Joe Verghese; Cuiling Wang; Richard B Lipton; Roee Holtzer
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-09-17       Impact factor: 6.053

10.  Gait dysfunction in mild cognitive impairment syndromes.

Authors:  Joe Verghese; Matthew Robbins; Roee Holtzer; Molly Zimmerman; Cuiling Wang; Xiaonan Xue; Richard B Lipton
Journal:  J Am Geriatr Soc       Date:  2008-05-14       Impact factor: 5.562

View more
  3 in total

1.  Associations of Circulating Insulin-Growth Factor-1 With Cognitive Functions and Quality of Life Domains in Ambulatory Young Adults With Cerebral Palsy: A Pilot Study.

Authors:  Ted Kheng Siang Ng; Patricia C Heyn; Alex Tagawa; Christina Coughlan; James J Carollo
Journal:  Front Neurol       Date:  2022-06-27       Impact factor: 4.086

2.  Neuroimaging Applications for Diagnosis and Therapy of Pathologies in the Central and Peripheral Nervous System.

Authors:  Silvia Middei
Journal:  Brain Sci       Date:  2022-02-01

3.  Endothelial PDGF-BB/PDGFR-β signaling promotes osteoarthritis by enhancing angiogenesis-dependent abnormal subchondral bone formation.

Authors:  Zhuang Cui; Hangtian Wu; Ye Xiao; Ting Xu; Junjie Jia; Hancheng Lin; Rongmin Lin; Kun Chen; Yihuang Lin; Kaiqun Li; Xiaohu Wu; Changjun Li; Bin Yu
Journal:  Bone Res       Date:  2022-08-29       Impact factor: 13.362

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.